○ Human lifespan benefit: not established by the compiled studies. Included records: the uncontrolled prospective studies concern clinical telomere disease, often with marrow failure; they do not establish a healthy-aging lifespan benefit.

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase expression is low in many differentiated normal tissues, while some normal proliferating cells can express it. Cancer can also use telomere maintenance; the included human records do not resolve long-term cancer risk from pharmacological activation. Tellingly, the FDA-approved telomerase inhibitor — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Synthetic androgen (studied off-label in telomere disease)

Also known as: danazol

Relationship to telomere biology: The US label describes danazol as a synthetic steroid with weak androgenic activity. Laboratory studies cited by Townsley2016 supplied a telomerase-related rationale for its use in clinical telomere disease. That trial could not reliably measure telomerase activity in the patients and did not establish that this mechanism caused the observed changes.

Regulatory status

The US prescribing label lists danazol as a prescription medicine for endometriosis amenable to hormonal management and prevention of hereditary angioedema attacks. The included telomere-disease study is investigational/off-label relative to those listed indications; the label does not list an aging indication. Androgenic and hepatic adverse effects are described in the label and the study.

Mechanism

Androgen-related telomerase expression is a mechanistic rationale. In the uncontrolled Townsley 2016 study, telomere and blood-count changes were observed, not a randomized demonstration of causal benefit.

Animal lifespan evidence

Animal lifespan evidence: none in this dataset

No animal lifespan study in this dataset. The androgen evidence here is human, in rare telomere-biology disorders.

This is separate from human lifespan evidence, which is none for every intervention on this site. A mouse lifespan result is not a human lifespan result, and a telomere change is not a lifespan result in either species.

Evidence — Human (prospective clinical trial — rare disease population) verify: source publication identified; see evidence and limitations

Species / population	27 patients with clinical telomere disease, median age 41 (range 17–66). Table 1 reports 19 with moderate aplastic anemia, 4 with severe aplastic anemia and 2 with myelodysplastic syndrome; eligibility also allowed pulmonary fibrosis. Six had no identified pathogenic mutation.
Exposure, route, schedule	Oral danazol 800 mg/day for up to 24 months.
Comparator / duration	Single-arm prospective trial with a pre-specified 24-month telomere-attrition endpoint. The institutional review board closed it early after observing the results; no efficacy stopping rule had been pre-specified.
Endpoint / numeric result	At 24 months, 12/12 evaluable patients met the primary reduced-attrition endpoint; intention-to-treat response was 12/27 (44%). Telomere elongation occurred in 11/12 evaluable patients (92%), a separate result. Hematologic response was 19/24 at 3 months and 10/12 at 24 months. Elevated liver enzymes and muscle cramps were reported in 41% and 33%. No randomized control group.
What it did NOT establish	This uncontrolled study concerns clinical telomere disease, not healthy aging. It cannot establish a causal survival benefit or benefits in the general population. Some participants had no identified pathogenic mutation. Liver-enzyme elevations, cramps and other adverse events limit interpretation of tolerability.

Negative or null findings

The US prescribing label reports hepatic and androgenic adverse effects, some potentially persistent. Observed blood-count or telomere changes in an uncontrolled study do not establish a general clinical benefit or safety profile.
The separate Clé2023 single-arm nandrolone study reported telomere and blood-count changes in some evaluable patients. Frequent liver-test abnormalities, acne and virilization occurred; grade3possibly related adverse events and four deaths during treatment were reported. The authors did not attribute the deaths to nandrolone but could not exclude an unlikely association with the intracranial hemorrhages. This is clinical telomere-disease evidence with substantial limitations.

Danazol (androgen)